drugset / Trial / NCT02509624
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
Timeline
- Start
- 2015-08-18
- Primary completion
- 2015-12-15
- Completion
- 2015-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selonsertib | Small molecule | 6 mg | Oral |